Lack of CD8 <sup>+</sup> T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer
-
- Brendan L. Horton
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
-
- Duncan M. Morgan
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
-
- Noor Momin
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
-
- Maria Zagorulya
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
-
- Elen Torres-Mejia
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
-
- Vidit Bhandarkar
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
-
- K. Dane Wittrup
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
-
- J. Christopher Love
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
-
- Stefani Spranger
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
説明
<jats:p> A lung cancer–specific form of CD8 <jats:sup>+</jats:sup> T cell dysfunction is established during T cell priming and contributes to ICB resistance. </jats:p>
収録刊行物
-
- Science Immunology
-
Science Immunology 6 (64), eabi8800-, 2021-10-29
American Association for the Advancement of Science (AAAS)
